Novo Nordisk today announced plans to invest 4.1 billion US dollars…to build a second fill and finishing manufacturing facility in Clayton, North Carolina, and grow its ability to produce current and future injectable treatments for people with obesity and other serious chronic diseases.
NVO’s total 2024 cap-ex for manufacturing is expected to be $6.8B, up from $3.9B in 2023.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”